Skip to main content

Pentasa Disease Interactions

There are 2 disease interactions with Pentasa (mesalamine).

Moderate

Mesalamine (applies to Pentasa) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure. Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease. Liver function should be evaluated prior to initiation of therapy and periodically during therapy.

References

  1. "Product Information. Pentasa (mesalamine)." Hoechst Marion Roussel
  2. "Product Information. Lialda (mesalamine)." Shire US Inc (2022):
Moderate

Mesalamine (applies to Pentasa) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus. Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies. Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease. Renal function should be evaluated prior to initiation of therapy and periodically during therapy.

References

  1. Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442
  2. Mehta RP "Acute interstitial nephritis due to 5-aminosalicylic acid." Can Med Assoc J 143 (1990): 1031-2
  3. Masson EA, Rhodes JM "Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss." Gut 33 (1992): 563-4
  4. Thuluvath PJ, Ninkovic M, Calam J, Anderson M "Mesalazine induced interstitial nephritis." Gut 35 (1994): 1493-6
  5. "Product Information. Asacol (mesalamine)." Procter and Gamble Pharmaceuticals (2022):
  6. "Product Information. Rowasa (mesalamine)." Solvay Pharmaceuticals Inc (2022):
  7. "Product Information. Pentasa (mesalamine)." Hoechst Marion Roussel
  8. "Product Information. Dipentum (olsalazine)." Meda Pharmaceuticals (2001):
  9. Wilcox GM, Reynolds JR, Galvanek EG "Nephrotoxicity associated with olsalazine." Am J Med 100 (1996): 238-40
  10. "Product Information. Colazal (balsalazide)." Salix Pharmaceuticals (2001):
View all 10 references

Pentasa drug interactions

There are 115 drug interactions with Pentasa (mesalamine).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.